PTC axes utreloxastat program after phase 2 ALS failure
But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show if twice daily oral dosing of utreloxastat could achieve a two-point difference on ALSFRS, an instrument for evaluating the functional status of ALS patients. The drug candidate fell short of that bar.
PTC Therapeutics may reeling from the failure of its amyotrophic lateral sclerosis (ALS) drug utreloxastat yesterday, but the ...
Philadelphia dad Eric Brunner was diagnosed with amyotrophic lateral sclerosis, the fatal disease known as ALS. He wants to ...
Live Science on MSN1d
'Exercise juice' released by muscles helps nerves grow, study findsIn a new study of mouse cells, scientists found that both the biochemical and mechanical effects of exercise may help injured ...
PTC Therapeutics halts Utreloxastat development after ALS trial disappoints. Analysts highlight promising pipeline, including ...
A team from IIT-BHU is developing a revolutionary cell-based device using 3D bioprinting technology to potentially cure ...
Bank of America Securities analyst Tazeen Ahmad maintained a Sell rating on PTC Therapeutics (PTCT – Research Report) yesterday and set a price ...
Widetrial is supporting an expanded access program (EAP) to bring MN-166 (ibudilast) to ALS patients ineligible for clinical ...
GlobalData on MSN1d
MaaT Pharma eyes Phase II after early success in ALS microbiome trialThe company’s oral, microbiome-changing therapy was well tolerated in patients with amyotrophic lateral sclerosis.
MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral ...
A team at IIT (BHU) is developing a revolutionary cell-based medical device using 3D bioprinting technology aimed at curing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback